ArticleOncoTargets and therapy2016
Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis.BMC cancer · 2019Pooled it
- Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies.Frontiers in oncology · 2026Review
- AI-guided design of a CXCR4-targeted core-shell nanocarrier for co-delivery of berberine/paclitaxel in cancer therapy.Journal of nanobiotechnology · 2025Article
- Investigating the Epigenetic Therapeutic Potential of Natural Compounds in Cancer.International journal of molecular sciences · 2025Review
- Natural Alkaloids in Cancer Therapy: Berberine, Sanguinarine and Chelerythrine against Colorectal and Gastric Cancer.International journal of molecular sciences · 2024Review
- MicroRNA 429 regulates MMPs expression by modulating TIMP2 expression in colon cancer cells and inflammatory colitis.Genes & genomics · 2024Article
- Pharmacological Potential of Three Berberine-Containing Plant Extracts Obtained fromBiomedicines · 2024Article
- Ferroptosis-Regulated Natural Products and miRNAs and Their Potential Targeting to Ferroptosis and Exosome Biogenesis.International journal of molecular sciences · 2024Review
- Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications.International journal of molecular sciences · 2024Review
- Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy.Frontiers in immunology · 2024Review
- Cancer Pathways Targeted by Berberine: Role of microRNAs.Current medicinal chemistry · 2024Review
- The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1.Aging · 2023Article
- Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers.Cell biology and toxicology · 2023Review
- Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways.Molecules (Basel, Switzerland) · 2022Review
- Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review.Molecules (Basel, Switzerland) · 2022Review
- Evodiamine Relieve LPS-Induced Mastitis by Inhibiting AKT/NF-κB p65 and MAPK Signaling Pathways.Inflammation · 2022Article
- lncRNA NEAT1 Downregulation Ameliorates the Myocardial Infarction of Mice by Regulating the miR-582-5p/F2RL2 Axis.Cardiovascular therapeutics · 2022Article
- Berberine as a Potential Agent for the Treatment of Colorectal Cancer.Frontiers in medicine · 2022Review
- Berberine as a Potential Anticancer Agent: A Comprehensive Review.Molecules (Basel, Switzerland) · 2021Review
- Berberine inhibits the proliferation, invasion and migration of endometrial stromal cells by downregulating miR‑429.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of epithelial organization and deregulated microRNAs are hallmarks of malignant carcinomas, but the relationship between them has been poorly understood. This study was designed to investigate the changes in the expression of E-cadherin, Par3, and miR-429 during the development of human colorectal cancer (CRC). E-cadherin and Par3 levels were quantitatively detected by immunohistochemistry and Western blotting. An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429. Our results suggested that E-cadherin and Par3 were remarkably decreased in tumor tissues compared with those in normal tissues, and miR-429 was upregulated in tumor tissues. After treatment of BER and EVO, the level of miR-429 was lower in tumor tissues than in normal tissues. This study investigated the potential relationship between miR-429, E-cadherin, and Par3 in CRC. The data suggested that BER and EVO can be potential therapeutic agents for CRC, as they downregulated the expression level of miR-429.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.